

# Mayestrotense<sup>®</sup>

IV injection *Amp.*




Your **heart** in  
The Experts  
Hands . . .

IV injection *Amp.*®  
**Mayestrotense**  
Propranolol Hcl 1 mg / ml

Mayestrotense ampoule 1 mg/ml of Propranolol Hydrochloride is the standard synthetic Beta-adrenergic receptors blocker used for the emergency treatment of cardiac dysrhythmias and Thyrotoxic crisis.<sup>(1)</sup>

Series of 225 patients RESISTANT TO DIGITALIS With average dose of 1 to 5 mg intravenous Propranolol hydrochloride<sup>(1)</sup>






IV injection **Amp.**®


# Mayestrotense

**Propranolol Hcl 1 mg / ml**

**Efficacy of IV. Propranolol for Suppression of Inducibility of Ventricular Tachyarrhythmias in CAD.<sup>(2)</sup>**



Mayestrotense injection has a dose response effects in patients with Coronary Heart Disease.<sup>(3)</sup>



IV injection **Amp.®**

# Mayestrotense

**Propranolol Hcl 1 mg / ml**

## Mayestrotense:

- 1) Decrease the activity of both normal and ectopic pacemaker cells.
- 2) Decrease the A-V nodal conduction velocity.

## Mayestrotense Indications:

- ♥ **The Emergency Treatment of Cardiac Dysrhythmias including:**
  - 💉 Supraventricular Arrhythmias.
  - 💉 Ventricular Tachycardias.
  - 💉 Tachyarrhythmias of Digitalis intoxication.
  - 💉 Resistant Tachyarrhythmias of excess catecholamine action during anesthesia.
- ♥ **The Emergency Treatment of Thyrotoxic crisis.**

## Mayestrotense contraindications:

- . Patients with known hypersensitivity to propranolol Hcl.
- . Cardiogenic Shock. . Sinus Bradycardia. . Bronchial Asthma.

## Mayestrotense Dose:

1 Mg (1 ml) injected over 1 minute,  
repeated at 2 minutes intervals  
until a response is observed.  
Maximum dose 10 mg in conscious  
patients & 5 mg in anesthetic patients.

## References:

1- Daily Med current medication information. 2- Am J Cardiol 1989 Dec 1;64(19):1305-9. Efficacy of intravenous propranolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristic in coronary artery disease. 3- U.S. National Library of Medicine.

*For further information please contact Egypharma Scientific office,  
12 Moez Eldawla st., Makram Ebied-Nasr City.  
Tel & Fax: 02 227 082 22 - mob: 010 003 25 60  
E-Mail:egypharmaco@yahoo.com*

